Cost effectiveness of nonpharmacological prevention programs for diabetes: A systematic review of trial‐based studies

Author:

Xiong Yongyi1ORCID,Huo Zhaohua1ORCID,Wong Samuel Y. S.1ORCID,Yip Benjamin H. K.1ORCID

Affiliation:

1. Jockey Club School of Public Health and Primary Care, Prince of Wales Hospital The Chinese University of Hong Kong Shatin Hong Kong China

Abstract

AbstractTrial‐based economic value of prevention programs for diabetes is inexplicit. We aimed to review the cost‐effectiveness of nonpharmacological interventions to prevent type‐2 diabetes mellitus (T2DM) for high‐risk people. Six electronic databases were searched up to March 2022. Studies assessing both the cost and health outcomes of nonpharmacological interventions for people at high‐risk of T2DM were included. The quality of the study was assessed by the Consolidated Health Economic Evaluation Reporting Standards 2022 checklist. The primary outcome for synthesis was incremental cost‐effectiveness ratios (ICER) for quality‐adjusted life years (QALYs), and costs were standardized in 2022 US dollars. Narrative synthesis was performed, considering different types and delivery methods of interventions. Sixteen studies included five based on the US diabetes prevention program (DPP), six on non‐DPP‐based lifestyle interventions, four on health education, and one on screening plus lifestyle intervention. Compared with usual care, lifestyle interventions showed higher potential of cost‐effectiveness than educational interventions. Among lifestyle interventions, DPP‐based programs were less cost‐effective (median of ICERs: $27,077/QALY) than non‐DPP‐based programs (median of ICERs: $1395/QALY) from healthcare perspectives, but with larger decreases in diabetes incidence. Besides, the cost‐effectiveness of interventions was more possibly realized through the combination of different delivery methods. Different interventions to prevent T2DM in high‐risk populations are both cost‐effective and feasible in various settings. Nevertheless, economic evidence from low‐ and middle‐income countries is still lacking, and interventions delivered by trained laypersons and combined with peer support sessions or mobile technologies could be potentially a cost‐effective solution in such settings with limited resources.

Publisher

Wiley

Reference47 articles.

1. IDF diabetes Atlas: global, regional and country‐level diabetes prevalence estimates for 2021 and projections for 2045;Sun H;Diabetes Res Clin Pract,2022

2. Organization WH. Diabetes. World Health Organization. Accessed February 15 2023 2023.https://www.who.int/news-room/fact-sheets/detail/diabetes

3. Service NH. NHS Diabetes Prevention Programme (NHS DPP). NHS England. Accessed February 3 2023 2023.https://www.england.nhs.uk/diabetes/diabetes-prevention/

4. Obesity and Diabetes

5. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3